SCHEMBL14320604

SCHEMBL14320604

CS(=O)(=O)c1cccc(-c2nc(Nc3ccc4c(c3)NC(=O)CC4)c3[nH]ncc3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 2/20 0.44
PTK2 Q05397 2/20 0.44
PTK2B Q14289 2/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
CDK7 P50613 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 3/20 0.39
LMNA P02545 3/20 0.39
KMT2A Q03164 2/20 0.39
PIK3CA P42336 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TP53 P04637 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14321132 0.92 JAK1 (0.42) ULK1PTK2PTK2BCDK1CCNB1
SCHEMBL14320521 0.90 CYP1A2 (0.48) SMN1; SMN2KDM4ELMNAKMT2AALDH1A1
SCHEMBL15650996 0.87 JAK1 (0.41) CDK1CCNB1SMN1; SMN2KDM4ELMNA
SCHEMBL14320794 0.86 ALDH1A1 (0.42) ULK1SMN1; SMN2ALDH1A1KIF11SYK
SCHEMBL15651130 0.85 CYP1A2 (0.47) SMN1; SMN2KDM4ELMNAKMT2AALDH1A1
SCHEMBL14320820 0.85 CRBN (0.48) ULK1KDM4ELMNAPIK3CATP53
SCHEMBL14320319 0.85 MEN1 (0.43) KMT2AMEN1SYKROCK2
SCHEMBL14320383 0.84 SYK (0.37) ULK1SMN1; SMN2KDM4ELMNAKMT2A
SCHEMBL14320698 0.84 PIK3CA (0.49) SMN1; SMN2KDM4ELMNAKMT2APIK3CA
SCHEMBL14320338 0.83 SYK (0.39) ULK1SMN1; SMN2KDM4ELMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ULK1 359/4885PTK2 31/4885PTK2B 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.